| Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. | |
| | |
MedLine Citation:
|
PMID: 11029459 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Transforming growth factor-beta1 (TGF-beta1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. Each of three Ki-ras(G12V) transfectants of HD6-4 colon cancer cells had been shown to be more aggressive in vivo than controls in earlier studies (Yan, Z., Chen, M., Perucho, M., and Friedman, E. (1997) J. Biol. Chem. 272, 30928-30936). We now show that stable expression of oncogenic Ki-ras(G12V) converts the HD6-4 colon cancer cell line from insensitive to TGF-beta1 to growth-promoted by TGF-beta1. Each of three Ki-ras(G12V) transfectants responded to TGF-beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TGF-beta1. The wild-type Ki-ras transfectants lack functional TGF-beta receptors, whereas all three Ki-ras(G12V) transfectants expressed functional TGF-beta receptors that bound (125)I-TGF-beta1. The previous studies showed that in cells with wild-type Ki-ras, TGF-beta receptors were not mutated, and receptor proteins were transported to the cell surface, but post-translational modification of TGF-beta receptor III (TbetaRIII) was incomplete. We now show that the betaglycan form of TbetaRIII is highly modified following translation when transiently expressed in Ki-ras(G12V) cells, whereas no such post-translational modification of TbetaRIII occurs in control cells. Antisense oligonucleotides directed to Ki-Ras decreased both TbetaRIII post-translational modification in Ki-ras(G12V) cells and TGF-beta1 down-regulation of p21, demonstrating the direct effect of mutant Ras. Therefore, one mechanism by which mutant Ki-Ras confers a more aggressive tumor phenotype is by enhancing TbetaRIII post-translational modification. |
| | |
Authors:
|
Z Yan; X Deng; E Friedman |
Related Documents
:
|
12496369 - Targeted disruption of the 25-hydroxyvitamin d3 1alpha-hydroxylase gene in ras-transfor... 21520099 - Active lymphangiogenesis is a major risk factor for anastomotic leakage following sphin... 1996309 - Activated protooncogenes in human lung tumors from smokers. 12526919 - Mevastatin can increase toxicity in primary amls exposed to standard therapeutic agents... 2650939 - Transformed nih 3t3 cells expressing human melanoma n-ras oncogene metastasize to lymph... 15389589 - Alpha-interferon and its effects on signal transduction pathways. 12724209 - Unanswered questions about the role of promoter methylation in carcinogenesis. 17021749 - P53 protein accumulation as a prognostic marker in sporadic colorectal cancer. 19773449 - Comparative analyses of chromosome alterations in soft-tissue metastases within and acr... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The Journal of biological chemistry Volume: 276 ISSN: 0021-9258 ISO Abbreviation: J. Biol. Chem. Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2001-03-06 Completed Date: 2001-04-05 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 2985121R Medline TA: J Biol Chem Country: United States |
Other Details:
|
Languages: eng Pagination: 1555-63 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Upstate Medical University, State University of New York, Syracuse, New York 13210, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Activin Receptors, Type I* Animals Cell Division Colonic Neoplasms / genetics*, pathology* Cyclin-Dependent Kinase Inhibitor p21 Cyclins / metabolism Enzyme Inhibitors Genes, ras* Humans Neoplasm Invasiveness Phenotype Protein Processing, Post-Translational* Protein-Serine-Threonine Kinases / genetics, metabolism Proteoglycans / genetics*, metabolism* Rats Receptors, Transforming Growth Factor beta / genetics*, metabolism* Recombinant Proteins / metabolism, pharmacology Reverse Transcriptase Polymerase Chain Reaction Transfection Transforming Growth Factor beta / pharmacology Tumor Cells, Cultured |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA75708/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/CDKN1A protein, human; 0/Cdkn1a protein, rat; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Cyclins; 0/Enzyme Inhibitors; 0/Proteoglycans; 0/Receptors, Transforming Growth Factor beta; 0/Recombinant Proteins; 0/Transforming Growth Factor beta; 145170-29-2/betaglycan; EC 2.7.1.11/TGF-beta type I receptor; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.30/Activin Receptors, Type I |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiat...
Next Document: Fe3+ coordination and redox properties of a bacterial transferrin.